A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy

About this Study
Sponsor Protocol ID:64407564MMY3002
IRB Number:2023-72
Actively Enrolling
Interventional
Phase 3
November 20, 2023
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No
Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:Stephanie Elkins
How to participate in our Clinical Trials